Nasdaq · Healthcare

CUMBERLAND PHARMACEUTICALS INC (CPIX)

As-reported financials and recent SEC filings for CUMBERLAND PHARMACEUTICALS INC, latest fiscal period FY2025. Every figure is pulled straight from the company’s EDGAR filings — no estimates.

Snapshot

Revenue

$44.5M

Net income

$-2.8M

Net margin

-6.4%

Diluted EPS

$-0.19

ROE

-11.6%

P/E (TTM)

—

Market cap

—

Debt / equity

—

Income statement (as reported)

Line	FY2025	FY2024	FY2023	FY2022	FY2021
Revenue	$44.5M	$37.9M	$39.6M	$42.0M	$35.0M
Gross profit	$37.9M	$31.3M	$33.5M	$32.9M	$26.2M
Operating income	$-2.8M	$-6.4M	$-9.6M	$-5.7M	$-7.7M
Net income	$-2.8M	$-6.5M	$-6.3M	$-5.6M	$-3.5M
Diluted EPS	$-0.19	$-0.46	$-0.44	$-0.38	$-0.24

Source: company XBRL financial statements on SEC EDGAR.

Recent SEC filings

8-K2026-07-01

8-K2026-06-25

DEFM14A2026-05-26

PREM14A2026-05-15

10-Q2026-05-08

8-K2026-05-05

8-K2026-04-24

DEFA14A2026-04-23

Largest Healthcare peers

UNH

UNITEDHEALTH GROUP INC

All Healthcare companies →

Go deeper on CPIX

Search CUMBERLAND PHARMACEUTICALS INC’s filings with cited answers, compare it against peers, build an operating model, and track it in your portfolio — all in one place.

Start free

Or check your whole portfolio free — no account needed.

Data sourced from SEC EDGAR (public domain). Figures are as-reported and may be unaudited or restated; verify against the source filing before relying on them. Informational only — not investment advice.